Gefitinib plus chemotherapy versus placebo plus chemotherapy in EGFR-mutation-positive non-small-cell lung cancer after progression on first-line gefitinib (IMPRESS): a phase 3 randomised trial-Reference-Cited by-同舟云学术

Gefitinib plus chemotherapy versus placebo plus chemotherapy in EGFR-mutation-positive non-small-cell lung cancer after progression on first-line gefitinib (IMPRESS): a phase 3 randomised trial

Published:2015-08 Issue:8 Volume:16 Page:990-998
ISSN:1470-2045
Container-title:The Lancet Oncology
language:en
Short-container-title:The Lancet Oncology

Author:

Soria Jean-Charles,Wu Yi-Long,Nakagawa Kazuhiko,Kim Sang-We,Yang Jin-Ji,Ahn Myung-Ju,Wang Jie,Yang James Chih-Hsin,Lu You,Atagi Shinji,Ponce Santiago,Lee Dae Ho,Liu Yunpeng,Yoh Kiyotaka,Zhou Jian-Ying,Shi Xiaojin,Webster Alan,Jiang Haiyi,Mok Tony S K

Publisher

Elsevier BV

Subject

Oncology

Reference27 articles.

1. Treating patients with EGFR-sensitizing mutations: first line or second line—is there a difference?;Mok;J Clin Oncol,2013

2. Metastatic non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up;Reck;Ann Oncol,2014

3. First-SIGNAL: first-line single-agent Iressa versus gemcitabine and cisplatin trial in never-smokers with adenocarcinoma of the lung;Han;J Clin Oncol,2012

4. LUX-Lung 3: a randomized, open-label, phase III study of afatinib versus pemetrexed and cisplatin as first-line treatment for patients with advanced adenocarcinoma of the lung harboring EGFR-activating mutations;Yang;Proc Am Soc Clin Oncol,2012

5. Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR;Maemondo;N Engl J Med,2010

Cited by 365 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Immunotherapy in EGFR-Mutant Non–Small Cell Lung Cancer: End of the Road or the First Chapter?;Journal of Clinical Oncology;2024-08-26

2. Safety and Efficacy of Gefitinib Administration After Osimertinib-Induced Interstitial Lung Disease: A Six-Case Series;OncoTargets and Therapy;2024-08

3. Tepotinib plus osimertinib in patients with EGFR-mutated non-small-cell lung cancer with MET amplification following progression on first-line osimertinib (INSIGHT 2): a multicentre, open-label, phase 2 trial;The Lancet Oncology;2024-08

4. Organometallic–Erlotinib Conjugates Active against Lung Cancer Cells and as Emerging Virus Entry Inhibitors;Organometallics;2024-07-22

5. Real-world outcomes of pemetrexed-platinum chemotherapy plus osimertinib after progression on first-line osimertinib in advanced EGFR-mutated NSCLC;Lung Cancer;2024-07